New BCO Content on Recently Approved Immunotherapy Jemperli

moderators

Jemperli (chemical name: dostarlimab-gxly) is approved by the U.S. Food and Drug Administration (FDA) to treat mismatch repair deficient (dMMR) advanced-stage breast cancer that has grown during or after treatment if no other treatment options are available.

Jemperli also is approved to treat dMMR advanced-stage endometrial cancer that has grown after treatment with platinum chemotherapy.

Learn more about:

• How Jemperli works
  
• Is Jemperli right for you?
  
• What to expect when taking Jemperli
  
• Jemperli side effects

Read more.